138.79
前日終値:
$141.36
開ける:
$141.205
24時間の取引高:
920.26K
Relative Volume:
0.55
時価総額:
$5.82B
収益:
$4.06B
当期純損益:
$413.08M
株価収益率:
17.33
EPS:
8.01
ネットキャッシュフロー:
$560.48M
1週間 パフォーマンス:
+17.16%
1か月 パフォーマンス:
-0.20%
6か月 パフォーマンス:
-35.56%
1年 パフォーマンス:
-39.68%
Charles River Laboratories International Inc Stock (CRL) Company Profile
名前
Charles River Laboratories International Inc
セクター
電話
781-222-6000
住所
251 BALLARDVALE ST, WILMINGTON, MA
CRL を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
CRL
Charles River Laboratories International Inc
|
138.79 | 5.82B | 4.06B | 413.08M | 560.48M | 8.01 |
![]()
TMO
Thermo Fisher Scientific Inc
|
403.13 | 159.89B | 42.90B | 6.52B | 6.72B | 17.05 |
![]()
DHR
Danaher Corp
|
189.73 | 142.45B | 23.82B | 3.77B | 4.90B | 5.15 |
![]()
IDXX
Idexx Laboratories Inc
|
491.70 | 37.95B | 3.93B | 894.97M | 837.70M | 10.82 |
![]()
A
Agilent Technologies Inc
|
106.93 | 30.97B | 6.53B | 1.26B | 1.31B | 4.35 |
![]()
IQV
Iqvia Holdings Inc
|
148.99 | 26.72B | 15.50B | 1.33B | 2.16B | 7.34 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-05-08 | アップグレード | Evercore ISI | In-line → Outperform |
2025-03-21 | ダウングレード | Goldman | Buy → Neutral |
2025-03-04 | アップグレード | Citigroup | Sell → Neutral |
2025-03-03 | アップグレード | Redburn Atlantic | Sell → Neutral |
2025-01-22 | ダウングレード | William Blair | Outperform → Mkt Perform |
2025-01-17 | ダウングレード | UBS | Buy → Neutral |
2024-11-18 | ダウングレード | CLSA | Hold → Underperform |
2024-11-07 | アップグレード | CLSA | Underperform → Hold |
2024-10-23 | 開始されました | CLSA | Underperform |
2024-10-14 | 開始されました | Redburn Atlantic | Sell |
2024-10-07 | ダウングレード | Evercore ISI | Outperform → In-line |
2024-10-02 | ダウングレード | BofA Securities | Buy → Neutral |
2024-10-01 | ダウングレード | Citigroup | Neutral → Sell |
2024-08-08 | ダウングレード | JP Morgan | Overweight → Neutral |
2024-08-08 | ダウングレード | Robert W. Baird | Outperform → Neutral |
2024-06-28 | ダウングレード | Argus | Buy → Hold |
2024-06-07 | 開始されました | Mizuho | Neutral |
2024-06-06 | 開始されました | Goldman | Buy |
2024-02-15 | ダウングレード | Guggenheim | Buy → Neutral |
2023-09-13 | 開始されました | TD Cowen | Market Perform |
2023-07-10 | ダウングレード | Citigroup | Buy → Neutral |
2023-02-23 | アップグレード | Guggenheim | Neutral → Buy |
2023-01-12 | ダウングレード | Jefferies | Buy → Hold |
2022-09-30 | アップグレード | Jefferies | Hold → Buy |
2022-08-25 | 開始されました | Credit Suisse | Outperform |
2022-08-04 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2022-05-24 | 開始されました | Guggenheim | Neutral |
2022-04-25 | ダウングレード | Jefferies | Buy → Hold |
2022-04-07 | 開始されました | Stephens | Overweight |
2022-02-17 | 繰り返されました | BofA Securities | Buy |
2022-02-17 | アップグレード | Citigroup | Neutral → Buy |
2022-02-17 | 繰り返されました | Deutsche Bank | Buy |
2022-02-17 | 繰り返されました | Morgan Stanley | Overweight |
2022-02-17 | 繰り返されました | UBS | Buy |
2021-08-05 | 再開されました | Credit Suisse | Neutral |
2020-12-16 | ダウングレード | Citigroup | Buy → Neutral |
2020-09-10 | アップグレード | Jefferies | Hold → Buy |
2020-07-01 | アップグレード | BofA Securities | Neutral → Buy |
2020-05-13 | アップグレード | UBS | Neutral → Buy |
2020-04-21 | ダウングレード | Jefferies | Buy → Hold |
2020-03-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2020-03-02 | 開始されました | Deutsche Bank | Buy |
2020-02-18 | アップグレード | Wolfe Research | Peer Perform → Outperform |
2020-01-10 | アップグレード | Goldman | Neutral → Buy |
2020-01-08 | 開始されました | Wells Fargo | Overweight |
2020-01-07 | 開始されました | Citigroup | Buy |
2019-10-18 | ダウングレード | BofA/Merrill | Buy → Neutral |
2019-06-10 | 開始されました | SVB Leerink | Outperform |
2019-04-30 | 再開されました | Evercore ISI | Outperform |
2018-12-14 | 開始されました | Deutsche Bank | Buy |
2018-10-09 | 開始されました | UBS | Neutral |
2018-08-23 | アップグレード | Raymond James | Mkt Perform → Outperform |
2018-07-17 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
2018-06-15 | アップグレード | KeyBanc Capital Mkts | Sector Weight → Overweight |
2018-02-14 | アップグレード | SunTrust | Hold → Buy |
すべてを表示
Charles River Laboratories International Inc (CRL) 最新ニュース
Charles River extends gains as Evercore upgrades after Q1 beat - MSN
Charles river raises 2025 guidance with focus on NAMs and cost optimization - MSN
Charles River surges after Q1 beat, guidance raise - MSN
Deutsche Bank lifts Charles River Labs target to $180 By Investing.com - Investing.com South Africa
Evercore ISI lifts Charles River Labs stock rating to Outperform By Investing.com - Investing.com Canada
Charles River Labs Stock Soars On Strategic Review Plan With Elliott: Retail Investors Optimistic - MSN
What 10 Analyst Ratings Have To Say About Charles River - Benzinga
Charles River stock upgraded at Evercore ISI (CRL:NYSE) - Seeking Alpha
Charles River (CRL) Stock Target Price Raised by Barclays Analyst | CRL Stock News - GuruFocus
Charles River (CRL) Target Price Raised by Baird Analyst | CRL Stock News - GuruFocus
Charles River Laboratories International, Inc. (NYSE:CRL) Q1 2025 Earnings Call Transcript - Insider Monkey
Jefferies Adjusts Price Target on Charles River Laboratories International to $142 From $100, Maintains Hold Rating - marketscreener.com
What Is Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Doing? - Yahoo Finance
Charles River (CRL) Sees Price Target Boost After Positive Q1 Insights | CRL Stock News - GuruFocus
Charles River (CRL) Receives Boost After Q1 Success | CRL Stock News - GuruFocus
Charles River Laboratories International Inc (CRL) Q1 2025 Earnings Call Highlights: Navigating ... - Yahoo
Evercore ISI lifts Charles River Labs stock rating to Outperform - Investing.com Australia
Charles River Laboratories Reports Q1 2025 Results - TipRanks
Decoding Charles River Laboratories International Inc (CRL): A S - GuruFocus
Health Care Stocks Climb As Companies Show Strong Gains - Finimize
Charles River Labs Stock Soars On Strategic Review Plan With Elliott: Retail Investors Optimistic By Stocktwits - Investing.com India
Charles River announces strategic review including 'examination of various alternatives' - MSN
Charles River Labs reshapes board, plans strategic review By Investing.com - Investing.com Canada
Charles River Labs Q1 2025 slides: Beats expectations, raises guidance amid NAMs transition - Investing.com Canada
Charles River (CRL) Stock Upgraded Following Strong Q1 Results | - GuruFocus
Charles River (CRL) Stock Upgraded Following Strong Q1 Results | CRL Stock News - GuruFocus
Charles River Laboratories International Q1 2025 Earnings Call Transcript - MarketBeat
Charles River: Q1 Earnings Snapshot - Midland Daily News
Charles River to initiate a review amid Elliott stakeIs a sale next? - Investing.com Canada
Charles River agrees with Elliott to add new directors, review business - Reuters
Charles River Laboratories (CRL) Adjusts 2025 Guidance Amid Revenue Decline - GuruFocus
Why Are Charles River Laboratories (CRL) Shares Soaring Today - Yahoo Finance
Charles River Labs agrees to strategic review, board shakeup amid activist pressure - The Business Journals
Charles River Laboratories' Q1 Earnings Beat Consensus, Stock Trades Higher On Signs Of Demand Stabilization - Benzinga
Top Stock Moves Now: Charles River Labs, Disney, Supermicro, and More - MSN
Earnings call transcript: Charles River Labs beats Q1 2025 earnings expectations - Investing.com
Charles River Laboratories (CRL) Shares Surge Following Strategic Review Announcement - GuruFocus
Charles River Labs Stock Soars as Firm Shakes Up Board, Launches Review - Investopedia
Charles River Laboratories (CRL) Surges on Strong Q1 Results and Upgraded Outlook - GuruFocus
Charles River to Conduct Strategic Review, Signs Cooperation Deal With Elliott Investment Management - marketscreener.com
CRL Q1 Earnings & Revenues Beat Estimates, Stock Rises, '25 View Up - TradingView
Compared to Estimates, Charles River (CRL) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
Charles River stock surges after Q1 beat (CRL:NYSE) - Seeking Alpha
Charles River Laboratories International to Initiate Comprehensive Review of its Business to Enhance Long-Term Stockholder Value - marketscreener.com
Charles River Boosts FY25 Outlook; Stock Up 22% On Strategic Review AnnouncementUpdate - Nasdaq
Charles River Labs: Balancing Strong Q1 Performance with Market Uncertainties – Hold Rating Maintained - TipRanks
Charles River Laboratories Q1 Non-GAAP Earnings Rise, Revenue Falls - marketscreener.com
Charles River Laboratories’s (NYSE:CRL) Q1: Strong Sales, Stock Jumps 22.4% - Yahoo Finance
Charles River Laboratories (CRL) Beats Q1 Earnings and Revenue Estimates - Yahoo Finance
Charles River Laboratories Announces First-Quarter 2025 Results - BioSpace
CRL Revises FY Revenue Growth Forecast Following DSA Segment Improvement | CRL Stock News - GuruFocus
Charles River Laboratories International Inc (CRL) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):